{
    "organizations": [],
    "uuid": "7645a6fa6496e970489a3acbbe3f5139c04310c1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-fda-releases-theratechnologies-fro/brief-fda-releases-theratechnologies-from-post-approval-commitments-related-to-egrifta-idUSASC09YK0",
    "ord_in_thread": 0,
    "title": "BRIEF-FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1 (Reuters) - Theratechnologies Inc:\n* FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTAÂ® (TESAMORELIN FOR INJECTION)\n* THERATECHNOLOGIES - FDA DETERMINED LARGE-SCALE POST-APPROVAL TRIALS NO LONGER REQUIRED AS CURRENT LABELING ADEQUATELY REFLECTS SAFETY PROFILE OF EGRIFTA\n* THERATECHNOLOGIES - FOR YEAR ENDED NOV 30, 2017, CO ESTIMATED POST-APPROVAL COMMITMENTS WILL REQUIRE $13 MILLION INVESTMENT, WHICH WILL NO LONGER BE NEEDED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-01T19:46:00.000+03:00",
    "crawled": "2018-05-02T16:05:41.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "theratechnologies",
        "inc",
        "fda",
        "release",
        "theratechnologies",
        "commitment",
        "related",
        "tesamorelin",
        "injection",
        "theratechnologies",
        "fda",
        "determined",
        "trial",
        "longer",
        "required",
        "current",
        "labeling",
        "adequately",
        "reflects",
        "safety",
        "profile",
        "egrifta",
        "theratechnologies",
        "year",
        "ended",
        "nov",
        "co",
        "estimated",
        "commitment",
        "require",
        "million",
        "investment",
        "longer",
        "needed",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}